{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:06:34Z","timestamp":1785179194167,"version":"3.55.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40259-020-00449-4","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T11:03:18Z","timestamp":1602586998000},"page":"733-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Immunotherapy Landscape in Renal Cell Carcinoma"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5231-4859","authenticated-orcid":false,"given":"Landon C.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-0441","authenticated-orcid":false,"given":"Kunal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-3531","authenticated-orcid":false,"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"issue":"1","key":"449_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clgc.2018.10.002","volume":"17","author":"AM Saad","year":"2019","unstructured":"Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: A SEER-based study. Clin Genitourin Cancer. 2019;17(1):46\u201357 (e45).","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"449_CR2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/ng.2708","volume":"45","author":"AA Hakimi","year":"2013","unstructured":"Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat Genet. 2013;45(8):849\u201350.","journal-title":"Nat Genet"},{"issue":"5","key":"449_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7(5):277\u201385.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"449_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"22","key":"449_CR5","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584\u201390.","journal-title":"J Clin Oncol"},{"issue":"5","key":"449_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427\u201334.","journal-title":"N Engl J Med"},{"issue":"33","key":"449_CR7","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422\u20138.","journal-title":"J Clin Oncol"},{"issue":"9605","key":"449_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103\u201311.","journal-title":"Lancet"},{"issue":"6","key":"449_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"449_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"issue":"22","key":"449_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271\u201381.","journal-title":"N Engl J Med"},{"issue":"9637","key":"449_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"19","key":"449_CR13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814\u201323.","journal-title":"N Engl J Med"},{"issue":"7","key":"449_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327.","journal-title":"Lancet Oncol"},{"issue":"15","key":"449_CR15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473\u201382.","journal-title":"Lancet Oncol"},{"issue":"1","key":"449_CR16","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/S1470-2045(15)00543-4","volume":"17","author":"RJ Motzer","year":"2016","unstructured":"Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016;17(1):e4\u20135.","journal-title":"Lancet Oncol"},{"issue":"10","key":"449_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","volume":"10","author":"BI Rini","year":"2009","unstructured":"Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992\u20131000.","journal-title":"Lancet Oncol"},{"issue":"23","key":"449_CR18","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","volume":"17","author":"KJ Gotink","year":"2011","unstructured":"Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011;17(23):7337\u2013466.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"449_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13402-015-0218-8","volume":"38","author":"KJ Gotink","year":"2015","unstructured":"Gotink KJ, Rovithi M, de Haas RR, Honeywell RJ, Dekker H, Poel D, et al. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr). 2015;38(2):119\u201329.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"449_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011;6(1):17\u201327.","journal-title":"Target Oncol"},{"issue":"1","key":"449_CR21","first-page":"31","volume":"1845","author":"M Buczek","year":"2014","unstructured":"Buczek M, Escudier B, Bartnik E, Szczylik C, Czarnecka A. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochim Biophys Acta. 2014;1845(1):31\u201341.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"449_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70(3):1063\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"449_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00280-013-2333-4","volume":"73","author":"CS Harmon","year":"2014","unstructured":"Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, et al. Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-naive patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014;73(1):151\u201361.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"449_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","volume":"13","author":"HT Tran","year":"2012","unstructured":"Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827\u201337.","journal-title":"Lancet Oncol"},{"issue":"10","key":"449_CR25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/onc.2010.503","volume":"30","author":"JC Welti","year":"2011","unstructured":"Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene. 2011;30(10):1183\u201393.","journal-title":"Oncogene"},{"issue":"37","key":"449_CR26","doi-asserted-by":"publisher","first-page":"13373","DOI":"10.1073\/pnas.1404848111","volume":"111","author":"EB Rankin","year":"2014","unstructured":"Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, et al. Direct regulation of GAS6\/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci USA. 2014;111(37):13373\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"449_CR27","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","volume":"70","author":"JS Ko","year":"2010","unstructured":"Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70(9):3526\u201336.","journal-title":"Cancer Res"},{"issue":"1","key":"449_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","volume":"15","author":"Y Crawford","year":"2009","unstructured":"Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009;15(1):21\u201334.","journal-title":"Cancer Cell"},{"issue":"16","key":"449_CR29","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.1073\/pnas.0902280106","volume":"106","author":"F Shojaei","year":"2009","unstructured":"Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 2009;106(16):6742\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"449_CR30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12885-019-5716-z","volume":"19","author":"S Pal","year":"2019","unstructured":"Pal S, Gong J, Mhatre SK, Lin SW, Surinach A, Ogale S, et al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer. 2019;19(1):548.","journal-title":"BMC Cancer"},{"issue":"13","key":"449_CR31","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","volume":"28","author":"BI Rini","year":"2010","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137\u201343.","journal-title":"J Clin Oncol"},{"key":"449_CR32","first-page":"CD001425","volume":"1","author":"C Coppin","year":"2005","unstructured":"Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;1:CD001425.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"449_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0094-0143(21)00487-0","volume":"20","author":"MP Wirth","year":"1993","unstructured":"Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am. 1993;20(2):283\u201395.","journal-title":"Urol Clin N Am"},{"issue":"2","key":"449_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cncr.23552","volume":"113","author":"JA Klapper","year":"2008","unstructured":"Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293\u2013301.","journal-title":"Cancer"},{"issue":"12","key":"449_CR35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907\u201313.","journal-title":"JAMA"},{"issue":"4","key":"449_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.7326\/0003-4819-108-4-518","volume":"108","author":"RI Fisher","year":"1988","unstructured":"Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988;108(4):518\u201323.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"449_CR37","first-page":"S55","volume":"6","author":"RI Fisher","year":"2000","unstructured":"Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl 1):S55\u201357.","journal-title":"Cancer J Sci Am"},{"issue":"3","key":"449_CR38","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688\u201396.","journal-title":"J Clin Oncol"},{"issue":"3","key":"449_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","volume":"21","author":"DF McDermott","year":"2015","unstructured":"McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, et al. The high-dose aldesleukin \"select\" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(3):561\u20138.","journal-title":"Clin Cancer Res"},{"issue":"11 Suppl 13","key":"449_CR40","first-page":"11","volume":"16","author":"RN Schwartz","year":"2002","unstructured":"Schwartz RN, Stover L, Dutcher JP. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16(11 Suppl 13):11\u201320.","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"449_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1464-410X.1989.tb05147.x","volume":"63","author":"RT Oliver","year":"1989","unstructured":"Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63(2):128\u201331.","journal-title":"Br J Urol"},{"issue":"6","key":"449_CR42","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313.","journal-title":"Nat Med"},{"issue":"8","key":"449_CR43","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18(8):1009\u2013211.","journal-title":"Lancet Oncol"},{"issue":"1","key":"449_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y Senbabaoglu","year":"2016","unstructured":"Senbabaoglu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17(1):231.","journal-title":"Genome Biol"},{"issue":"19","key":"449_CR45","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"449_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"key":"449_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"issue":"34","key":"449_CR48","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35(34):3851\u20138.","journal-title":"J Clin Oncol"},{"issue":"14","key":"449_CR49","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"10","key":"449_CR50","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DF, Aren Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370\u201385.","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"449_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.2020.38.6_suppl.609","volume":"38","author":"NM Tannir","year":"2020","unstructured":"Tannir NM, McDermott DF, Escudier B, Hammers HJ, Aren OR, Plimack ER, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020;38(6_suppl):609\u2013609.","journal-title":"J Clin Oncol"},{"issue":"5","key":"449_CR52","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMp030061","volume":"349","author":"DJ George","year":"2003","unstructured":"George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med. 2003;349(5):419\u201321.","journal-title":"N Engl J Med"},{"issue":"Pt 2","key":"449_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","volume":"52","author":"PS Hegde","year":"2018","unstructured":"Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt 2):117\u201324.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"449_CR54","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248\u201364.","journal-title":"Cell"},{"issue":"6","key":"449_CR55","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148\u201357.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"449_CR56","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","volume":"181","author":"S Kusmartsev","year":"2008","unstructured":"Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181(1):346\u201353.","journal-title":"J Immunol"},{"issue":"5","key":"449_CR57","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"449_CR58","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.","journal-title":"Nat Commun"},{"key":"449_CR59","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel M, Rigamonti N, Kadioglu E, Cassara A, Wyser Rmili C, Kiialainen A, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9:385.","journal-title":"Sci Transl Med"},{"issue":"14","key":"449_CR60","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1128\/MCB.01254-12","volume":"33","author":"S Ghosh","year":"2013","unstructured":"Ghosh S, Paul A, Sen E. Tumor necrosis factor alpha-induced hypoxia-inducible factor 1alpha-beta-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling. Mol Cell Biol. 2013;33(14):2718\u201331.","journal-title":"Mol Cell Biol"},{"issue":"5706","key":"449_CR61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"key":"449_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9:385.","journal-title":"Sci Transl Med"},{"issue":"3","key":"449_CR63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405\u201315.","journal-title":"Lancet Oncol"},{"issue":"12","key":"449_CR64","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"449_CR65","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1200\/JCO.2020.38.15_suppl.5001","volume":"38","author":"ER Plimack","year":"2020","unstructured":"Plimack ER, Rini BI, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): updated analysis of KEYNOTE-426. J Clin Oncol. 2020;38(15_suppl):5001\u20135001.","journal-title":"J Clin Oncol"},{"issue":"12","key":"449_CR66","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103\u201315.","journal-title":"N Engl J Med"},{"issue":"10189","key":"449_CR67","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404\u201315.","journal-title":"Lancet"},{"issue":"2","key":"449_CR68","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/cancers12020408","volume":"12","author":"C Buonerba","year":"2020","unstructured":"Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, et al. Outcomes associated with first-line anti-PD-1\/PD-L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-analysis. Cancers (Basel). 2020;12(2):408.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"449_CR69","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/2326-6066.CIR-17-0475","volume":"6","author":"RR McKay","year":"2018","unstructured":"McKay RR, Boss\u00e9 D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, et al. The clinical activity of PD-1\/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res. 2018;6(7):758\u201365.","journal-title":"Cancer Immunol Res"},{"issue":"15_suppl","key":"449_CR70","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2019.37.15_suppl.4500","volume":"37","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate\/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019;37(15_suppl):4500\u20134500.","journal-title":"J Clin Oncol"},{"issue":"6230","key":"449_CR71","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"7681","key":"449_CR72","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","volume":"551","author":"M Luksza","year":"2017","unstructured":"Luksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517\u201320.","journal-title":"Nature"},{"issue":"1","key":"449_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","volume":"20","author":"JM Conroy","year":"2018","unstructured":"Conroy JM, Pabla S, Glenn ST, Burgher B, Nesline M, Papanicolau-Sengos A, et al. Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors. J Mol Diagn. 2018;20(1):95\u2013109.","journal-title":"J Mol Diagn"},{"issue":"1","key":"449_CR74","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-018-0344-8","volume":"6","author":"C Morrison","year":"2018","unstructured":"Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, et al. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018;6(1):32.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"449_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41571-019-0209-1","volume":"16","author":"RR Kotecha","year":"2019","unstructured":"Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol. 2019;16(10):621\u201333.","journal-title":"Nat Rev Clin Oncol"},{"key":"449_CR76","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.cellimm.2018.01.013","volume":"343","author":"G Badalamenti","year":"2019","unstructured":"Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listi A, Maragliano R, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol. 2019;343:103753.","journal-title":"Cell Immunol"},{"key":"449_CR77","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179.","journal-title":"Sci Rep"},{"issue":"5","key":"449_CR78","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ijc.30138","volume":"139","author":"J Berntsson","year":"2016","unstructured":"Berntsson J, Nodin B, Eberhard J, Micke P, Jirstrom K. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer. 2016;139(5):1129\u201339.","journal-title":"Int J Cancer"},{"issue":"1","key":"449_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12865-018-0241-4","volume":"19","author":"J Jackute","year":"2018","unstructured":"Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S, et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018;19(1):3.","journal-title":"BMC Immunol"},{"issue":"15","key":"449_CR80","doi-asserted-by":"publisher","first-page":"13835","DOI":"10.18632\/oncotarget.3453","volume":"6","author":"I Levi","year":"2015","unstructured":"Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, et al. Characterization of tumor infiltrating natural killer cell subset. Oncotarget. 2015;6(15):13835\u2013433.","journal-title":"Oncotarget"},{"issue":"6371","key":"449_CR81","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"15_suppl","key":"449_CR82","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2019.37.15_suppl.4570","volume":"37","author":"SS Tykodi","year":"2019","unstructured":"Tykodi SS, Donskov F, Lee J-L, Szczylik C, Malik J, Alekseev BY, et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated results for KEYNOTE-427 cohort A. J Clin Oncol. 2019;37(15_suppl):4570\u20134570.","journal-title":"J Clin Oncol"},{"issue":"13","key":"449_CR83","first-page":"1426","volume":"2","author":"R Payne","year":"2014","unstructured":"Payne R, Glenn L, Hoen H, Richards B, Smith JW 2nd, Lufkin R, et al. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer. 2014;2(13):1426\u20132051.","journal-title":"J Immunother Cancer"},{"key":"449_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40425-016-0174-5","volume":"4","author":"S Chow","year":"2016","unstructured":"Chow S, Galvis V, Pillai M, Leach R, Keene E, Spencer-Shaw A, et al. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. J Immunother Cancer. 2016;4:67.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"449_CR85","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-017-0307-5","volume":"5","author":"B Curti","year":"2017","unstructured":"Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, et al. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017;5(1):102.","journal-title":"J Immunother Cancer"},{"issue":"7_suppl","key":"449_CR86","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2019.37.7_suppl.657","volume":"37","author":"JA Chatzkel","year":"2019","unstructured":"Chatzkel JA, Swank J, Ludlow S, Lombardi K, Croft C, Artigas Y, et al. Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: a single center, single arm trial. J Clin Oncol. 2019;37(7_suppl):657\u2013657.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"449_CR87","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2018.36.15_suppl.4500","volume":"36","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, Lee J-L, Szczylik C, Donskov F, Malik J, Alekseev BY, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. J Clin Oncol. 2018;36(15_suppl):4500\u20134500.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"449_CR88","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1200\/JCO.2019.37.15_suppl.4569","volume":"37","author":"J-L Lee","year":"2019","unstructured":"Lee J-L, Ziobro M, Gafanov R, Matveev VB, Suarez C, Donskov F, et al. KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC). J Clin Oncol. 2019;37(15_suppl):4569\u20134569.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"449_CR89","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2018.36.15_suppl.3006","volume":"36","author":"A Diab","year":"2018","unstructured":"Diab A, Hurwitz ME, Cho DC, Papadimitrakopoulou V, Curti BD, Tykodi SS, et al. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: preliminary phase 1\/2 results of PIVOT. J Clin Oncol. 2018;36(15_suppl):3006\u20133006.","journal-title":"J Clin Oncol"},{"issue":"6","key":"449_CR90","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/jjco\/hyz026","volume":"49","author":"Y Tomita","year":"2019","unstructured":"Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, et al. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. Jpn J Clin Oncol. 2019;49(6):506\u201314.","journal-title":"Jpn J Clin Oncol"},{"issue":"15_suppl","key":"449_CR91","doi-asserted-by":"publisher","first-page":"TPS4595","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4595","volume":"37","author":"NM Tannir","year":"2019","unstructured":"Tannir NM, Agarwal N, Pal SK, Formiga MN, Guo J, George DJ, et al. A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma. J Clin Oncol. 2019;37(15_suppl):TPS4595.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"449_CR92","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1200\/JCO.2018.36.6_suppl.515","volume":"36","author":"RM Nadal","year":"2018","unstructured":"Nadal RM, Mortazavi A, Stein M, Pal SK, Davarpanah NN, Parnes HL, et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J Clin Oncol. 2018;36(6_suppl):515\u2013515.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"449_CR93","doi-asserted-by":"publisher","first-page":"TPS4598","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4598","volume":"36","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Apolo AB, Powles T, Escudier B, Aren OR, Shah A, et al. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). J Clin Oncol. 2018;36(15_suppl):TPS4598.","journal-title":"J Clin Oncol"},{"issue":"6 suppl","key":"449_CR94","doi-asserted-by":"publisher","first-page":"TPS767","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS767","volume":"38","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ. A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk. J Clin Oncol. 2020;38(6 suppl):TPS767.","journal-title":"J Clin Oncol"},{"issue":"12","key":"449_CR95","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","volume":"18","author":"P Bergerot","year":"2019","unstructured":"Bergerot P, Lamb P, Wang E, Pal SK. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther. 2019;18(12):2185\u201393.","journal-title":"Mol Cancer Ther"},{"key":"449_CR96","doi-asserted-by":"publisher","first-page":"viii308","DOI":"10.1093\/annonc\/mdy283.081","volume":"29","author":"N Agarwal","year":"2018","unstructured":"Agarwal N, Vaishampayan U, Green M, di Nucci F, Chang PY, Scheffold C, et al. Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: results of the dose escalation stage in patients (pts) with treatment-na\u00efve advanced renal cell carcinoma (RCC). Ann Oncol. 2018;29:viii308.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"449_CR97","doi-asserted-by":"publisher","first-page":"TPS4596","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4596","volume":"37","author":"T Zhang","year":"2019","unstructured":"Zhang T, Ballman KV, Choudhury AD, Chen RC, Watt C, Wen Y, et al. PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). J Clin Oncol. 2019;37(15_suppl):TPS4596.","journal-title":"J Clin Oncol"},{"issue":"4","key":"449_CR98","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/0008-5472.CAN-10-2360","volume":"71","author":"YG Yoo","year":"2011","unstructured":"Yoo YG, Christensen J, Huang LE. HIF-1alpha confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res. 2011;71(4):1244\u201352.","journal-title":"Cancer Res"},{"key":"449_CR99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13046-016-0298-y","volume":"35","author":"J Yang","year":"2016","unstructured":"Yang J, Zhang X, Zhang Y, Zhu D, Zhang L, Li Y, et al. HIF-2alpha promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. J Exp Clin Cancer Res. 2016;35:26.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"449_CR100","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jcma.2017.06.005","volume":"80","author":"E Lim","year":"2017","unstructured":"Lim E, Kuo CC, Tu HF, Yang CC. The prognosis outcome of oral squamous cell carcinoma using HIF-2alpha. J Chin Med Assoc. 2017;80(10):651\u20136.","journal-title":"J Chin Med Assoc"},{"issue":"6","key":"449_CR101","first-page":"101042831770963","volume":"39","author":"ZJ Gao","year":"2017","unstructured":"Gao ZJ, Wang Y, Yuan WD, Yuan JQ, Yuan K. HIF-2alpha not HIF-1alpha overexpression confers poor prognosis in non-small cell lung cancer. Tumour Biol. 2017;39(6):1010428317709637.","journal-title":"Tumour Biol"},{"issue":"38","key":"449_CR102","doi-asserted-by":"publisher","first-page":"e1646","DOI":"10.1097\/MD.0000000000001646","volume":"94","author":"Y Fan","year":"2015","unstructured":"Fan Y, Li H, Ma X, Gao Y, Chen L, Li X, et al. Prognostic significance of hypoxia-inducible factor expression in renal cell carcinoma: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2015;94(38):e1646.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"449_CR103","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11912-019-0752-z","volume":"21","author":"J Fallah","year":"2019","unstructured":"Fallah J, Rini BI. HIF inhibitors: status of current clinical development. Curr Oncol Rep. 2019;21(1):6.","journal-title":"Curr Oncol Rep"},{"issue":"18","key":"449_CR104","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","volume":"76","author":"EM Wallace","year":"2016","unstructured":"Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, et al. A small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 2016;76(18):5491\u2013500.","journal-title":"Cancer Res"},{"issue":"9","key":"449_CR105","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol. 2018;36(9):867\u201374.","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"449_CR106","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2019.37.7_suppl.558","volume":"37","author":"BI Rini","year":"2019","unstructured":"Rini BI, Appleman LJ, Figlin RA, Plimack ER, Merchan JR, Wang K, et al. Results from a phase I expansion cohort of the first-in-class oral HIF-2\u03b1 inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. J Clin Oncol. 2019;37(7_suppl):558\u2013558.","journal-title":"J Clin Oncol"},{"issue":"1 Supplement","key":"449_CR107","doi-asserted-by":"publisher","first-page":"B140","DOI":"10.1158\/1535-7163.MCT-17-0471","volume":"17","author":"TW Wong","year":"2018","unstructured":"Wong TW, Shrimali R, Contreras C, Cheng T, Czerwinski RM, Dixon DD, et al. Abstract B140: PT2977, a novel HIF-2a antagonist, has potent antitumor activity and remodels the immunosuppressive tumor microenvironment in clear cell renal cell cancer. Mol Cancer Ther. 2018;17(1 Supplement):B140\u2013B140140.","journal-title":"Mol Cancer Ther"},{"key":"449_CR108","doi-asserted-by":"crossref","unstructured":"Abstracts from the Sixteenth International Kidney Cancer Symposium, 2nd-3rd November 2017, Miami, Florida. Kidney Cancer. 2018;2:50.","DOI":"10.3233\/KCA-189001"},{"issue":"15_suppl","key":"449_CR109","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2018.36.15_suppl.2508","volume":"36","author":"KP Papadopoulos","year":"2018","unstructured":"Papadopoulos KP, Jonasch E, Zojwalla NJ, Wang K, Bauer TM. A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):2508\u20132508.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"449_CR110","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2020.38.6_suppl.611","volume":"38","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Plimack ER, Bauer TM, Merchan JR, Papadopoulos KP, McDermott DF, et al. Phase I\/II study of the oral HIF-2 \u03b1 inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). J Clin Oncol. 2020;38(6_suppl):611\u2013611.","journal-title":"J Clin Oncol"},{"key":"449_CR111","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","volume":"108","author":"M Auvray","year":"2019","unstructured":"Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108:33\u201340.","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"449_CR112","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2020.38.15_suppl.5005","volume":"38","author":"RR McKay","year":"2020","unstructured":"McKay RR, Xie W, McGregor BA, Braun DA, Wei XX, Kyriakopoulos C, et al. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): a response-based phase II study (OMNIVORE). J Clin Oncol. 2020;38(15_suppl):5005\u20135005.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"449_CR113","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1200\/JCO.2020.38.15_suppl.5006","volume":"38","author":"MB Atkins","year":"2020","unstructured":"Atkins MB, Jegede O, Haas NB, McDermott DF, Bilen MA, Drake CG, et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-na\u00efve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). J Clin Oncol. 2020;38(15_suppl):5006\u20135006.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"449_CR114","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2020.38.15_suppl.5008","volume":"38","author":"C-H Lee","year":"2020","unstructured":"Lee C-H, Shah AY, Hsieh JJ, Rao A, Pinto A, Bilen MA, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1\/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol. 2020;38(15_suppl):5008\u20135008.","journal-title":"J Clin Oncol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00449-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-020-00449-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00449-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T01:33:55Z","timestamp":1650245635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-020-00449-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00449-4","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"13 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Landon Brown and Dr Kunal Desai declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Dr Tian Zhang declares that she has research funding from Astra Zeneca, Janssen, OmniSeq, PGDx, Pfizer, Merrimack, Abbvie\/Stemcentrx, Novartis, Merck, Mirati, Astellas, and Regeneron; Advisory\/consultant role with Genentech Roche, Exelixis, Bayer, AstraZeneca, Pfizer, Sanofi-Aventis, Janssen, Foundation Medicine, Amgen, BMS, Merck, Pharmacyclics, and Seattle Genetics; Speakers\u2019 bureau for Genentech Roche (2018), Exelixis (2019), Sanofi-Aventis, Genomic Health\/Exact Sciences; and Stocks\/Employment from Capio Biosciences and Archimmune Therapeutics (spouse). Dr Moshe Ornstein declares research funding from Pfizer & Bristol-Myers Squibb; advisory\/consulting roles from Pfizer, Bristol-Myers Squibb, Exelixis; Speakers\u2019 bureau for Bristol Myers Squibb (2019) and Exelixis (2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Drs Landon Brown and Kunal Desai wrote the majority of the content. Drs Tian Zhang and Moshe Ornstein reviewed all content and provided editorial input.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}